Which statement best describes the relationship among MPPP, PEPAP, and MPTP?

• A. MPPP is an analog of Demerol; PEPAP is its cousin but more potent; effects: dizziness, drowsiness, visual disturbance, slight respiratory depression; lasting up to 3 hours; MPTP has no narcotic properties, but metabolized by the brain into a toxin that destroys nerve cells causing Parkinson-like disease.
• B. MPTP is an analog of Demerol; MPPP and PEPAP have no narcotic effects.
• C. PEPAP is a stimulant with no analgesic properties; MPPP is a hallucinogen; MPTP is a narcotic analgesic.
• D. AMF, not related to MPPP, PEPAP, or MPTP, is the only opioid.

Answer: (A)

The main idea is distinguishing opioid analgesic analogs from the neurotoxic compound MPTP and understanding how they relate to Demerol (meperidine). MPPP and PEPAP are synthetic analogs of Demerol, so they share opioid activity and produce typical narcotic effects such as dizziness, drowsiness, visual disturbances, and some respiratory depression, with effects lasting a few hours. In contrast, MPTP does not act as a narcotic; it is metabolized in the brain into a toxin (MPP+) that damages dopaminergic neurons, leading to Parkinson-like symptoms. So the best description is that MPPP and PEPAP are Demerol-like opioids with narcotic effects, while MPTP is non-narcotic but neurotoxic after brain metabolism. The other options misstate these relationships—for example, suggesting MPTP is an analog of Demerol or that PEPAP/MMPP have no narcotic effects, or introducing an unrelated opioid.